| Date | Title | Description |
| 12.07.2026 | Blood-Brain Barrier Crossed: Denali’s FDA Approval Unlocks Alzheimer’s Pipeline | By Jackie Manning
Published: Jul 12 2026, 6:57 AM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 06.03.2026 | FDA reversals leave investors worrying about the fates of other experimental drugs | The FDA in the past year has denied or discouraged applications of at least eight new drugs, according to RTW Investments. The agency initially refused to review Moderna’s flu shot before reversing course.
Companies have accused the FDA of ... |
| 03.09.2024 | Parkinson’s Disease Drug Market: Trends, Growth, and Segmentation | Share
Tweet
Share
Share
Email
Parkinson’s disease, a progressive neurodegenerative disorder characterized by motor symptoms such as tremors, rigidity, and bradykinesia, affects millions of individuals worldwide. As the global population age... |
| 15.03.2024 | HiLabs closes $39 million Series B financing | HiLabs a leading provider of AI-powered solutions to clean dirty data, unlocking its hidden potential for healthcare transformation closed a $39 million Series B financing.
The round was led by our Eight Roads Ventures India team and Denali... |
| 27.02.2024 | Denali Therapeutics Announces $500 million Private Placement Equity Financing | - |
| 27.09.2022 | FDA slaps a partial hold on Avidity's mAb-siRNA therapy, pausing enrollment in muscle weakness disease study | Avidity Biosciences will have to wait to enroll new patients in a Phase I/II study of its therapy for myotonic dystrophy type 1, or DM1, which weakens muscles and leads to respiratory and cardiac issues.
The FDA is dock... |
| 10.01.2022 | Denali Therapeutics : Announces Progression and Expansion of Broad Therapeutic Portfolio for Neurodegeneration and Expected Key Milestones in 2022 - Form 8-K | Denali Therapeutics Announces Progression and Expansion of Broad Therapeutic Portfolio for Neurodegeneration and Expected Key Milestones in 2022
•Key data readouts to include additional Phase 1/2 data on DNL310 (ETV:IDS) in MPS II (Hunter s... |
| 10.01.2022 | Denali Therapeutics Announces Progression and Expansion of Broad Therapeutic Portfolio for Neurodegeneration and Expected Key Milestones in 2022 | Key data readouts to include additional Phase 1/2 data on DNL310 (ETV:IDS) in MPS II (Hunter syndrome) and the first clinical data on DNL919 (ATV:TREM2), both potentially further validating Denali’s Transport Vehicle (TV) platform; in addit... |
| 06.10.2021 | Denali Therapeutics : Announces Positive Clinical Results and Regulatory Progress for Development Programs in Amyotrophic Lateral Sclerosis (ALS) | eIF2B activator DNL343 achieved safety and biomarker goals in a Phase 1 study in healthy volunteers; a Phase 1b study began in individuals with ALS in Q3 2021
Fast Track designation granted by the U.S. Food and Drug Administration (FDA) to ... |
| 29.09.2021 | Denali Therapeutics : Announces Upcoming Presentations on EIF2B Activator DNL343 and RIPK1 Inhibitor SAR443820/DNL788 at the 2021 Annual Northeast Amyotrophic Lateral Sclerosis (NEALS) Meeting | Denali to present results from Phase 1 healthy volunteer study of EIF2B activator DNL343
Sanofi to present Phase 2 study plans in ALS for RIPK1 inhibitor SAR443820
Denali to host analyst and investor webinar on October 6, at 4:30 p.m. Easte... |
| 12.02.2021 | Denali unveil proof-of-concept data for brain delivery tech in rare disease, with eyes on much bigger indications | Nearly a year after unveiling their brain delivery technology in Science Translational Medicine, Denali has delivered promising new results from a trial that used it on patients with a rare genetic disease and could... |
| 30.04.2019 | After amyloid failures, it’s time to take a new tack for treating Alzheimer’s | If insanity is doing the same thing over and over again but expecting different results, then the last decade or so of Alzheimer’s disease drug development has been insane. Three carefully designed, well-executed, and fully resourced trials... |
| 05.05.2018 | A life sciences firm run by a top VC and a cofounder of Alphabet’s life sciences arm, just raised its biggest fund yet | There’s no end to the number of fascinating devices and therapies being created right now in the fields of health and life sciences. The investors behind them are often pretty interesting, too, given the expertise needed to make informed be... |
| 21.12.2017 | Flagship Pioneering forges ahead with $618M capital raise | Fourteen of Flagship Pioneering’s portfolio companies have gone public in the past four years. This month early stage biotech business Denali Therapeutics (NASDAQ: DNLI) and 10-year-old diagnostics company Quanterix (NASDAQ: QTRX) each did ... |
| 04.12.2017 | Denali Therapeutics Announces Closing Of Initial Public Offering, Including Full Exercise Of Underwriters’ Option To Purchase Additional Shares | - |
| 27.11.2017 | Term Sheet — Monday, November 27 | THE END OF AN ERA
Good morning, Term Sheet readers.
Paid Content What you need to know about growing cyberattacks From ExtraHop
Meredith Corp, which owns Better Homes & Gardens and Family Circle, agreed to buy Time Inc for $18.50 a shar... |
| 14.11.2017 | Term Sheet — Tuesday, November 14 | THREE THINGS
Good morning, Term Sheet readers.
Paid Content Securing the enterprise without boundaries From ExtraHop
• A DFJ spokesperson told me Jurvetson left “by mutual agreement.”
• Meanwhile, Jurvetson tweeted that he’s leaving the fir... |
| 12.09.2017 | 23andMe raises $250M led by Sequoia Capital | Others in the genomics space that have raised funding include Counsyl, Veritas and Sophia
It's been 17 years since the Human Genome Project, led by Dr. Craig Venter, announced the mapping of the human genome, a breakthrough in science that ... |
| 03.11.2016 | The top 15 healthcare deals of 2016 | There has been $13.1 billion invested across 1,287 deals so far this year
Even as venture funding has slowed down this year, healthcare has remained one of the top spaces for companies to raise money.
In the first quarter of this year, even... |
| 28.08.2016 | Flagship Ventures Joins $130M Series B for Denali | Denali Therapeutics Inc. announced several critical milestones in the company's growth, including its first Clinical Trial Application to initiate a Phase 1 trial, previously undisclosed collaborations and licensing deals, and a $130 millio... |
| 28.08.2016 | ARCH Venture Joins $130M Series B for Denali | Denali Therapeutics Inc. announced several critical milestones in the company's growth, including its first Clinical Trial Application to initiate a Phase 1 trial, previously undisclosed collaborations and licensing deals, and a $130 millio... |
| 28.08.2016 | Flagship Ventures Joins $130M Series B for Denali | Denali Therapeutics Inc. announced several critical milestones in the company's growth, including its first Clinical Trial Application to initiate a Phase 1 trial, previously undisclosed collaborations and licensing deals, and a $130 millio... |
| 28.08.2016 | ARCH Venture Joins $130M Series B for Denali | Denali Therapeutics Inc. announced several critical milestones in the company's growth, including its first Clinical Trial Application to initiate a Phase 1 trial, previously undisclosed collaborations and licensing deals, and a $130 millio... |
| 26.08.2016 | Denali Therapeutics Grabs $130M |
SOUTH SAN FRANCISCO, CA, Denali Therapeutics, a biotech startup focused on neurodegenerative diseases led by former Genentech executives, has raised $130 million in Series B funding.
>> Click here for more funding data on Denali Th... |
| 25.08.2016 | Denali Therapeutics Raises $130M in Series B Funding | Denali Therapeutics, Inc., a San Francisco, CA-based developer of a diversified portfolio of therapeutics, raised $130m in Series B equity financing.
The round was led by Baillie Gifford, a UK-based mutual fund and included several new and ... |
| 25.08.2016 | Denali grabs another megaround while inking a flurry of neurodegeneration R&D pacts | South San Francisco-based upstart Denali Therapeutics has been busy. A little more than a year after making a splash with its $217 million startup round designed to fund a new breed of neurodegeneration drug developer, ... |
| 25.08.2016 | Denali Therapeutics announces first clinical trial application, key collaborations and $130M Series B | - |
| 12.12.2015 | Google’s (Alphabet’s) rising focus on health: 5 must-read stories from MedCity News this week | Watch the archived video above, and also check out five important stories we covered this week – the first of which being the center of our MedHeads discussion:
1. Google Ventures CEO: Our focus on the life sciences will grow
Nearly a third... |
| 07.12.2015 | Google Ventures CEO: Our focus on the life sciences will grow | That said, Google Ventures, newly christened “GV” per its new website, will reduce its investments in seed-stage startups, Maris told the Wall Street Journal. This is right in line with current life sciences investment practices, in which t... |
| 06.12.2015 | Sovereign wealth fund investment in healthcare is on the rise, especially in digital health | “Healthcare is a necessity for people and for the United States, the sector represents a significant proportion of GDP, Maduell said. “With regards to the United States, it remains a deep liquid market compared to other countries.”
Sovereig... |
| 15.05.2015 | Denali Therapeutics Launches with $217M in Funding | Denali Therapeutics Inc., a San Francisco, CA-based biotechnology company that develops treatments for neurodegenerative diseases, launched with $217m in funding.
The founding investors include Fidelity Biosciences, ARCH Venture Partners, F... |
| 19.04.2010 | Stealthy Denali Medical raises $4 million | By Thomas Lee
Denali Medical Inc., a Plymouth, Minn.-based medical device incubator, raised $4 million from investors, according to a filing with the Securities & Exchange Commission.
Not much is known about Denali, which is seeking $4.... |
| 16.04.2010 | Denali Medical raises $4 million | Promoted
Telemedicine’s potential to provide healthcare to the world’s most vulnerable
Teladoc Health Head of R&D Yulun Wang highlights the impact of virtual care in underserved populations around the globe through the World Telehealth ... |
| 10.09.2009 | Minnesota’s Denali Medical raises $2 million | Denali’s board members include Michael DeMane, the former chief operating officer at Medtronic who in April joined the venture firm Thomas, McNerney & Partners as a senior advisor. The company previously raised $3 million in 2007, accor... |
| - | Sovereign wealth fund investment in healthcare is on the rise, especially in digital health | In the past couple of years there has been a rise in sovereign wealth funds’ investments in healthcare. These cover a wide range of areas from hospital chains to pharmaceutical companies, but it also includes direct investments in digital h... |
| - | Google Ventures CEO: Our focus on the life sciences will grow | Nearly a third of Google Ventures‘ investments are in the life sciences, according to the firm’s president and CEO Bill Maris. It’s entering 2016 with $2.4 billion under management, Maris wrote in a blog – and says will continue to strength... |
| - | Google’s (Alphabet’s) rising focus on health: 5 must-read stories from MedCity News this week | Security issues in healthcare are racing to the forefront of importance these days. Case in point: Just a few days ago, Hospital Corporation of America had a major EHR outage just a few days ago, reportedly caused by a hardware storage glit... |
| - | Flagship Pioneering forges ahead with $618M capital raise | A Cambridge, Massachusetts-based venture capital fund has raised $618 million to invest in biotech and life science startups. Flagship Pioneering, which dates back to 2000 and was previously known as Flagship Ventures, seeds startups throug... |
| - | SIRION Biotech and Denali Therapeutics Join Forces | MUNICH - SIRION Biotech GmbH, a world leader in viral vector-based gene delivery technologies for gene & cell therapy, announced today that it signed a license and collaboration agreement with Denali Therapeutics, a biopharmaceutical co... |
